JP2015533490A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015533490A5 JP2015533490A5 JP2015532046A JP2015532046A JP2015533490A5 JP 2015533490 A5 JP2015533490 A5 JP 2015533490A5 JP 2015532046 A JP2015532046 A JP 2015532046A JP 2015532046 A JP2015532046 A JP 2015532046A JP 2015533490 A5 JP2015533490 A5 JP 2015533490A5
- Authority
- JP
- Japan
- Prior art keywords
- binding polypeptide
- residue
- glycan
- domain
- numbering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 150000004676 glycans Chemical class 0.000 claims 11
- 239000012636 effector Substances 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 235000001014 amino acid Nutrition 0.000 claims 8
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 6
- 125000005647 linker group Chemical group 0.000 claims 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 125000005629 sialic acid group Chemical group 0.000 claims 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 239000002619 cytotoxin Substances 0.000 claims 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- 101710112752 Cytotoxin Proteins 0.000 claims 2
- 102000009490 IgG Receptors Human genes 0.000 claims 2
- 108010073807 IgG Receptors Proteins 0.000 claims 2
- 125000003172 aldehyde group Chemical group 0.000 claims 2
- 239000000611 antibody drug conjugate Substances 0.000 claims 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000013595 glycosylation Effects 0.000 claims 2
- 238000006206 glycosylation reaction Methods 0.000 claims 2
- 150000002923 oximes Chemical class 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229930182830 galactose Chemical group 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2012/003819 | 2012-09-12 | ||
| PCT/EP2012/003819 WO2013037484A2 (en) | 2011-09-12 | 2012-09-12 | Anti-aplhabetatcr antibody |
| US201361776715P | 2013-03-11 | 2013-03-11 | |
| US61/776,715 | 2013-03-11 | ||
| PCT/US2013/059481 WO2014043361A1 (en) | 2012-09-12 | 2013-09-12 | Fc containing polypeptides with altered glycosylation and reduced effector function |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015533490A JP2015533490A (ja) | 2015-11-26 |
| JP2015533490A5 true JP2015533490A5 (enExample) | 2016-10-20 |
| JP6438397B2 JP6438397B2 (ja) | 2018-12-12 |
Family
ID=50278674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532046A Active JP6438397B2 (ja) | 2012-09-12 | 2013-09-12 | 変更されたグリコシル化および低減されたエフェクター機能を有するＦｃ含有ポリペプチド |
Country Status (34)
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| IL289918B2 (en) | 2013-03-11 | 2025-07-01 | Genzyme Corp | Site-specific antibody-drug conjugation through glycoengineering |
| HRP20230260T1 (hr) * | 2014-03-19 | 2023-04-28 | Genzyme Corporation | Glikoinženjering ciljajućih dijelova specifičan za mjesto |
| AU2015243512B2 (en) * | 2014-04-08 | 2020-06-04 | University Of Georgia Research Foundation Inc. | Site-specific antibody-drug glycoconjugates and methods |
| US10357472B2 (en) * | 2014-06-12 | 2019-07-23 | Cspc Dophen Corporation | Homogenous antibody drug conjugates via enzymatic methods |
| SG11201702786RA (en) * | 2014-10-09 | 2017-05-30 | Genzyme Corp | Glycoengineered antibody drug conjugates |
| TW202417497A (zh) | 2015-10-12 | 2024-05-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| EP3222292A1 (en) | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
| TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
| MX2019005397A (es) | 2016-11-08 | 2019-10-09 | Regeneron Pharma | Proteinas de union a antigeno que antagonizan el receptor de leptina. |
| WO2018107116A1 (en) * | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby |
| GB201717446D0 (en) * | 2017-10-24 | 2017-12-06 | Evox Therapeutics Ltd | Affinity purification of engineering extracellular vesicles |
| CA3084385A1 (en) | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof |
| HRP20250986T1 (hr) | 2018-04-06 | 2025-10-24 | Regeneron Pharmaceuticals, Inc. | Antitijelo agonista leptinskog receptora za upotrebu u povećanju koštane mase kod osobe koja pati od metaboličke disfunkcije ili hipoleptinemije |
| JP1640846S (enExample) * | 2018-10-16 | 2019-09-09 | ||
| KR20210093856A (ko) | 2018-11-21 | 2021-07-28 | 리제너론 파마슈티칼스 인코포레이티드 | 항-스타필로코쿠스 항체 및 이의 사용 |
| SG11202106658XA (en) | 2018-12-21 | 2021-07-29 | Regeneron Pharma | Rifamycin analogs and antibody-drug conjugates thereof |
| EP3917962A1 (en) | 2019-02-01 | 2021-12-08 | Regeneron Pharmaceuticals, Inc. | Anti-il2 receptor gamma antigen-binding proteins |
| AU2020248645A1 (en) * | 2019-03-27 | 2021-10-28 | Tigatx, Inc. | Engineered IgA antibodies and methods of use |
| CN120192414A (zh) | 2019-04-03 | 2025-06-24 | 建新公司 | 具有降低的断裂的抗αβTCR结合多肽 |
| JP2023525034A (ja) | 2020-05-08 | 2023-06-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法 |
| US20220098313A1 (en) | 2020-09-15 | 2022-03-31 | Regeneron Pharmaceuticals, Inc. | Use of LEPR Agonists for Pain |
| KR20220052098A (ko) | 2020-10-20 | 2022-04-27 | 주식회사 엘지에너지솔루션 | 마스킹 테이프를 이용한 전극 시편에 대한 물성 측정 시스템 및 이를 이용한 물성 측정 방법 |
| KR102576252B1 (ko) * | 2021-04-07 | 2023-09-11 | 아주대학교산학협력단 | 산화된 면역글로불린을 유효성분으로 포함하는 면역조절 기능 이상 관련 질환 예방 또는 치료용 약학적 조성물 |
| TW202325273A (zh) * | 2021-10-22 | 2023-07-01 | 美商杜夫特學院信託管理公司 | 靶向fap之中子捕獲劑及與其相關之用途及調配物 |
| WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
| KR20250058783A (ko) | 2022-07-29 | 2025-04-30 | 리제너론 파마슈티칼스 인코포레이티드 | 트랜스페린 수용체 1로 재표적화된 바이러스 입자 |
| WO2024026470A2 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:payload fusions and methods of use thereof |
| IL320016A (en) | 2022-11-04 | 2025-06-01 | Regeneron Pharma | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
| CN120456916A (zh) | 2022-11-14 | 2025-08-08 | 瑞泽恩制药公司 | 抗fgfr3抗体和抗原结合片段及其使用方法 |
| WO2024107765A2 (en) | 2022-11-14 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
| WO2024259206A1 (en) | 2023-06-16 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Cd40 x cd40 bispecific antigen-binding molecules and uses thereof |
| AR133384A1 (es) | 2023-07-28 | 2025-09-24 | Regeneron Pharma | Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida |
| TW202513801A (zh) | 2023-07-28 | 2025-04-01 | 美商雷傑納榮製藥公司 | 用於治療龐貝氏症之抗ＴｆＲ：ＧＡＡ及抗ＣＤ６３：ＧＡＡ插入 |
| WO2025088546A1 (en) | 2023-10-25 | 2025-05-01 | Ablynx N.V. | Fc domain variants with enhanced fc receptor binding |
| TW202540169A (zh) | 2023-11-08 | 2025-10-16 | 法商賽諾菲公司 | 基於ｃｄ２５的溶酶體降解物及其用途 |
| US20250242018A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| US20250242056A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| US20250277048A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| EP4616869A1 (en) * | 2024-03-15 | 2025-09-17 | Oncomatryx Biopharma, S.L. | Fap targeted antibody-drug conjugates |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
| GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| WO1997014719A1 (en) | 1995-10-16 | 1997-04-24 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| ATE386809T1 (de) | 1996-08-02 | 2008-03-15 | Bristol Myers Squibb Co | Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| AU3369999A (en) | 1998-04-02 | 1999-10-25 | Genentech Inc. | Antibody variants and fragments thereof |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| JP2002522063A (ja) | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | 増加した血清半減期を有する改変された分子の生成 |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| NZ539776A (en) | 1999-01-15 | 2006-12-22 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2002002781A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| CA2431600C (en) | 2000-12-12 | 2012-04-17 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| US20040002587A1 (en) * | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| CA2478011C (en) | 2002-03-01 | 2013-05-21 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| DK1534335T4 (en) | 2002-08-14 | 2015-10-05 | Macrogenics Inc | FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF |
| CN101987871A (zh) | 2002-09-27 | 2011-03-23 | 赞科股份有限公司 | 优化的Fc变体及其产生方法 |
| WO2004035752A2 (en) | 2002-10-15 | 2004-04-29 | Protein Design Labs, Inc. | ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS |
| ES2897506T3 (es) | 2003-01-09 | 2022-03-01 | Macrogenics Inc | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos |
| JP4629047B2 (ja) * | 2003-06-12 | 2011-02-09 | イーライ リリー アンド カンパニー | Ｇｌｐ−１アナログ複合タンパク質 |
| US8399618B2 (en) * | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| EP1697415A1 (en) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| CA2552788C (en) | 2004-01-12 | 2013-09-24 | Applied Molecular Evolution, Inc. | Fc region variants |
| WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| EP1799700A4 (en) * | 2004-09-27 | 2009-02-11 | Centocor Inc | SRAGE MIMETIC BODIES, COMPOSITIONS, PROCESSES AND USES |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| JP2008537941A (ja) * | 2005-03-31 | 2008-10-02 | ゼンコー・インコーポレイテッド | 最適化特性を有するＦｃ変異体 |
| BRPI0611445A2 (pt) * | 2005-05-09 | 2010-09-08 | Glycart Biotechnology Ag | molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica |
| EP1896503B1 (en) | 2005-05-31 | 2014-10-29 | Board of Regents, The University of Texas System | IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF |
| EP1896071B1 (en) | 2005-06-30 | 2015-04-29 | Janssen Biotech, Inc. | Methods and compositions with enhanced therapeutic activity |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US7833260B2 (en) | 2006-07-20 | 2010-11-16 | Orbusneich Medical, Inc. | Bioabsorbable polymeric medical device |
| EP2125893A2 (en) * | 2007-01-23 | 2009-12-02 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| WO2009130198A2 (en) * | 2008-04-21 | 2009-10-29 | Novo Nordisk A/S | Hyperglycosylated human coagulation factor ix |
| BR112013021526B1 (pt) * | 2011-02-25 | 2021-09-21 | Chugai Seiyaku Kabushiki Kaisha | Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio |
| TWI803876B (zh) | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| UY34317A (es) * | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
-
2013
- 2013-09-12 EA EA202091166A patent/EA202091166A1/ru unknown
- 2013-09-12 HR HRP20181354TT patent/HRP20181354T1/hr unknown
- 2013-09-12 MY MYPI2015000513A patent/MY170126A/en unknown
- 2013-09-12 ES ES18166377T patent/ES2950509T3/es active Active
- 2013-09-12 DK DK13766833.1T patent/DK2895513T3/en active
- 2013-09-12 SG SG10201701831VA patent/SG10201701831VA/en unknown
- 2013-09-12 NZ NZ705983A patent/NZ705983A/en unknown
- 2013-09-12 DK DK18166377.4T patent/DK3366705T5/da active
- 2013-09-12 LT LTEP13766833.1T patent/LT2895513T/lt unknown
- 2013-09-12 PT PT13766833T patent/PT2895513T/pt unknown
- 2013-09-12 PL PL13766833T patent/PL2895513T3/pl unknown
- 2013-09-12 PL PL18166377.4T patent/PL3366705T3/pl unknown
- 2013-09-12 ES ES13766833.1T patent/ES2684549T3/es active Active
- 2013-09-12 EP EP23164492.3A patent/EP4223783A3/en active Pending
- 2013-09-12 HU HUE18166377A patent/HUE062876T2/hu unknown
- 2013-09-12 AU AU2013315499A patent/AU2013315499B2/en active Active
- 2013-09-12 KR KR1020157009038A patent/KR102185151B1/ko active Active
- 2013-09-12 CA CA2884762A patent/CA2884762C/en active Active
- 2013-09-12 CN CN201380058863.8A patent/CN104797601B/zh active Active
- 2013-09-12 SG SG11201501521TA patent/SG11201501521TA/en unknown
- 2013-09-12 MA MA37949A patent/MA37949B1/fr unknown
- 2013-09-12 EP EP13766833.1A patent/EP2895513B1/en active Active
- 2013-09-12 HU HUE13766833A patent/HUE039337T2/hu unknown
- 2013-09-12 FI FIEP18166377.4T patent/FI3366705T3/fi active
- 2013-09-12 RS RS20230536A patent/RS64317B1/sr unknown
- 2013-09-12 SI SI201331144T patent/SI2895513T1/sl unknown
- 2013-09-12 HR HRP20230623TT patent/HRP20230623T1/hr unknown
- 2013-09-12 LT LTEP18166377.4T patent/LT3366705T/lt unknown
- 2013-09-12 CN CN201910721123.7A patent/CN110590953A/zh active Pending
- 2013-09-12 PE PE2015000327A patent/PE20150650A1/es active IP Right Grant
- 2013-09-12 RS RS20180981A patent/RS57748B1/sr unknown
- 2013-09-12 MX MX2015003234A patent/MX366103B/es active IP Right Grant
- 2013-09-12 KR KR1020227025572A patent/KR20220110855A/ko not_active Ceased
- 2013-09-12 SI SI201332053T patent/SI3366705T1/sl unknown
- 2013-09-12 WO PCT/US2013/059481 patent/WO2014043361A1/en not_active Ceased
- 2013-09-12 PT PT181663774T patent/PT3366705T/pt unknown
- 2013-09-12 JP JP2015532046A patent/JP6438397B2/ja active Active
- 2013-09-12 KR KR1020207033737A patent/KR102426488B1/ko active Active
- 2013-09-12 EP EP18166377.4A patent/EP3366705B1/en active Active
- 2013-09-12 EA EA201590545A patent/EA035987B1/ru unknown
- 2013-12-09 UA UAA201503410A patent/UA116995C2/uk unknown
-
2015
- 2015-03-02 ZA ZA2015/01417A patent/ZA201501417B/en unknown
- 2015-03-05 DO DO2015000050A patent/DOP2015000050A/es unknown
- 2015-03-06 TN TNP2015000085A patent/TN2015000085A1/fr unknown
- 2015-03-09 IL IL237640A patent/IL237640B/en active IP Right Grant
- 2015-03-11 CL CL2015000606A patent/CL2015000606A1/es unknown
- 2015-03-11 PH PH12015500528A patent/PH12015500528A1/en unknown
- 2015-03-12 MX MX2019007753A patent/MX2019007753A/es unknown
- 2015-03-19 CR CR20150147A patent/CR20150147A/es unknown
- 2015-04-10 EC ECIEPI201514133A patent/ECSP15014133A/es unknown
-
2018
- 2018-08-23 CY CY181100880T patent/CY1120909T1/el unknown
-
2019
- 2019-11-28 IL IL271027A patent/IL271027B/en active IP Right Grant
-
2020
- 2020-08-23 IL IL276866A patent/IL276866B/en unknown
-
2021
- 2021-09-29 IL IL286766A patent/IL286766A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015533490A5 (enExample) | ||
| JP2016512425A5 (enExample) | ||
| JP2016512426A5 (enExample) | ||
| WO2011091078A3 (en) | Antibody fc variants with enhanced complement activity | |
| PE20220938A1 (es) | Compuestos agonistas de gipr | |
| HRP20230623T1 (hr) | Polipeptidi koji sadrže fc domenu s promijenjenom glikozilacijom i smanjenom efektorskom funkcijom | |
| JP2014508759A5 (enExample) | ||
| RU2015142992A (ru) | Сайт-специфическая конъюгация антитело-лекарственное средство посредством гликоинженерии | |
| CN112888709B (zh) | 标靶cd22的构建体和其用途 | |
| JP2016026215A5 (enExample) | ||
| WO2008090959A1 (ja) | エフェクター活性が増強された遺伝子組換え抗体組成物 | |
| EA201070739A1 (ru) | Полипептиды с усиленными противовоспалительными и сниженными цитотоксическими свойствами и связанные с ними способы | |
| RU2016101711A (ru) | Высокостабильный т-клеточный рецептор и способ его получения и применения | |
| IL199263A (en) | Glucagon peptide with enhanced solubility, pharmaceutical composition containing it and its uses for drug preparation | |
| WO2013151672A3 (en) | Modified polynucleotides for the production of oncology-related proteins and peptides | |
| CN106413749B (zh) | 新颖全谱抗登革抗体 | |
| CN110114460A (zh) | 乳铁蛋白/白蛋白融合蛋白质及其制备方法 | |
| JP2015078191A5 (enExample) | ||
| JP2017515470A5 (enExample) | ||
| JP2014221758A5 (enExample) | ||
| NZ584893A (en) | PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF | |
| WO2013115926A3 (en) | Aspartyl-trna synthetase-fc conjugates | |
| JP2012510461A5 (enExample) | ||
| JP2013532644A5 (enExample) | ||
| SI2506868T1 (en) | HYPER AND HYBRID POLYPETTIDES FACTOR VIII-FC AND METHODS FOR THEIR USE |